AU778149B2 - Agonists specific for the peripheral cannabinoid receptor - Google Patents

Agonists specific for the peripheral cannabinoid receptor Download PDF

Info

Publication number
AU778149B2
AU778149B2 AU12458/01A AU1245801A AU778149B2 AU 778149 B2 AU778149 B2 AU 778149B2 AU 12458/01 A AU12458/01 A AU 12458/01A AU 1245801 A AU1245801 A AU 1245801A AU 778149 B2 AU778149 B2 AU 778149B2
Authority
AU
Australia
Prior art keywords
straight
branched chain
chain alkyl
hydrogen
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU12458/01A
Other languages
English (en)
Other versions
AU1245801A (en
Inventor
Aviva Breuer
Esther Fride
Aaron Garzon
Lumir Hanus
Michal Horowitz
Raphael Mechoulam
Susanna Tchilibon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU1245801A publication Critical patent/AU1245801A/en
Application granted granted Critical
Publication of AU778149B2 publication Critical patent/AU778149B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AU12458/01A 1999-10-31 2000-10-30 Agonists specific for the peripheral cannabinoid receptor Ceased AU778149B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL132661 1999-10-31
IL132661A IL132661A (en) 1999-10-31 1999-10-31 Agonists specific for peripheral cannabinoid receptors
PCT/US2000/029903 WO2001032169A1 (en) 1999-10-31 2000-10-30 Agonists specific for the peripheral cannabinoid receptor

Publications (2)

Publication Number Publication Date
AU1245801A AU1245801A (en) 2001-05-14
AU778149B2 true AU778149B2 (en) 2004-11-18

Family

ID=11073405

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12458/01A Ceased AU778149B2 (en) 1999-10-31 2000-10-30 Agonists specific for the peripheral cannabinoid receptor

Country Status (13)

Country Link
US (3) US6864291B1 (US06903137-20050607-C00013.png)
EP (1) EP1244440B1 (US06903137-20050607-C00013.png)
JP (1) JP4231906B2 (US06903137-20050607-C00013.png)
KR (1) KR100770695B1 (US06903137-20050607-C00013.png)
AT (1) ATE286389T1 (US06903137-20050607-C00013.png)
AU (1) AU778149B2 (US06903137-20050607-C00013.png)
CA (1) CA2385928A1 (US06903137-20050607-C00013.png)
DE (1) DE60017287T2 (US06903137-20050607-C00013.png)
HU (1) HUP0203681A3 (US06903137-20050607-C00013.png)
IL (2) IL132661A (US06903137-20050607-C00013.png)
NZ (1) NZ518054A (US06903137-20050607-C00013.png)
WO (1) WO2001032169A1 (US06903137-20050607-C00013.png)
ZA (1) ZA200202181B (US06903137-20050607-C00013.png)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
DE69910373T2 (de) 1998-05-04 2004-04-01 The University Of Connecticut, Farmington Analgetische und immunomodulierende cannabinoiden
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
JP2003511469A (ja) 1999-10-18 2003-03-25 ユニバーシティ オブ コネチカット 抹消カンナビノイド受容体（ｃｂ２）選択的配位子
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
JP2004532185A (ja) * 2001-01-26 2004-10-21 ユニバーシティ オブ コネチカット 新規なカンナビミメティックリガンド
US7173027B2 (en) * 2001-01-29 2007-02-06 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
WO2003005960A2 (en) * 2001-07-13 2003-01-23 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
CA2464333C (en) 2001-10-26 2011-07-26 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
TW200407110A (en) 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
WO2003061699A1 (fr) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedes pour affections allergiques
EP1469842A4 (en) * 2002-01-31 2006-04-26 Pharmos Corp BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS
IL150302A (en) * 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
CA2496097A1 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
US20060172019A1 (en) * 2003-03-07 2006-08-03 Ralston Stuart H Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
WO2005123053A2 (en) * 2004-06-22 2005-12-29 Pharmos Limited Use of cb2 receptors agonists for the treatment of huntington’s disease
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
CA2650566A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
WO2008001369A1 (en) * 2006-06-27 2008-01-03 Pharmos Corporation Use of cb2 receptor agonists for promoting neurogenesis
US9763894B2 (en) * 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
WO2008107879A1 (en) * 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel cannabidiol derivatives and their use as anti-inflammatory agents
JP2010540618A (ja) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド 幼児の成長および発達を増大するための内在性カンナビノイド
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2010041253A1 (en) 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions comprising cb receptor agonists, uses thereof and methods for their preparation
US20120277296A1 (en) 2009-07-23 2012-11-01 Sophie Lotersztajn Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease
ITMI20122221A1 (it) 2012-12-21 2014-06-22 C4T S C A R L Nuovi composti del 2,3-diidro-4h-1,3-benzossazin-4-one, metodo per prepararli e forma farmaceutica che li comprende
EP2986587B1 (en) 2013-04-17 2023-11-22 Sharon Anavi-Goffer Cb2 receptor ligands for the treatment of psychiatric disorders
EP2992880A1 (en) * 2014-09-04 2016-03-09 Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau Use of heme oxygenase 1 inducers and cannabinoid 2 receptor or delta-opioid receptor agonists in inflammatory pain
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US11612581B2 (en) 2017-08-09 2023-03-28 Cannibite Bvba Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects
WO2021080648A1 (en) * 2019-10-25 2021-04-29 Gelest Technologies, Inc. Silicon-based cannabidiol derivatives and compositions thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434295A (en) * 1994-02-07 1995-07-18 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL55274A (en) 1978-08-02 1982-08-31 Yissum Res Dev Co 4-(2,6-dihydroxy-4-(dimethylheptyl)phenyl)substituted 2-pinen-10-ol and pinane derivatives,their preparation and pharmaceutical compositions comprising them
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434295A (en) * 1994-02-07 1995-07-18 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds

Also Published As

Publication number Publication date
JP4231906B2 (ja) 2009-03-04
ZA200202181B (en) 2003-05-28
CA2385928A1 (en) 2001-05-10
DE60017287D1 (de) 2005-02-10
HUP0203681A2 (hu) 2003-04-28
AU1245801A (en) 2001-05-14
HUP0203681A3 (en) 2003-05-28
NZ518054A (en) 2003-10-31
KR100770695B1 (ko) 2007-10-29
US20050165118A1 (en) 2005-07-28
DE60017287T2 (de) 2005-12-08
EP1244440B1 (en) 2005-01-05
US6864291B1 (en) 2005-03-08
US7214716B2 (en) 2007-05-08
EP1244440A4 (en) 2003-05-14
US20020173528A1 (en) 2002-11-21
US6903137B2 (en) 2005-06-07
ATE286389T1 (de) 2005-01-15
IL148796A (en) 2008-11-26
KR20030008208A (ko) 2003-01-24
EP1244440A1 (en) 2002-10-02
IL132661A (en) 2008-11-26
WO2001032169A1 (en) 2001-05-10
JP2004505006A (ja) 2004-02-19
IL132661A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
AU778149B2 (en) Agonists specific for the peripheral cannabinoid receptor
JP2004505006A5 (US06903137-20050607-C00013.png)
EP1299374B1 (en) Novel non-psychotropic cannabinoids
JP2004503498A (ja) カンナビジオール誘導体を含んでなる医薬組成物
JPH08500096A (ja) （３ｒ，４ｒ）−δ▲上６▼−テトラヒドロカンナビノール−７−酸
JP2000500737A (ja) 腫瘍壊死因子α（ＴＮＦ−α）阻害性医薬品
Fride et al. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only
Galal et al. Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications
AU2003214608A1 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
AU2003209616B2 (en) Bicyclic CB2 cannabinoid receptor ligands
US20060128794A1 (en) Treatment of interstitial cystitis using (6aR,10aR)-delta8-tetrahydrocannabinol-11-OIC acids
US20050137251A1 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
WO2003063758A2 (en) Bicyclic cb2 cannabinoid receptor ligands
AU2003209616A1 (en) Bicyclic CB2 cannabinoid receptor ligands
WO2005123053A2 (en) Use of cb2 receptors agonists for the treatment of huntington’s disease
US20050032881A1 (en) Novel non-psychotropic cannabinoids
Buchwald Soft cannabinoid analogues as potential anti-glaucoma agents
WO2003064359A1 (en) Bicyclic cb2 cannabinoid receptor ligands
EP1785417A2 (en) Novel non-psychotropic cannabinoids
HUT74507A (en) Use of di-tert-butylphenol compounds for producing pharmaceutical compositions having anti-inflammatory effect